These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 15553665

  • 1. [Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432].
    Okamoto M, Ahmed SU, Oshikawa T, Tano T, Sato M.
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1627-30. PubMed ID: 15553665
    [Abstract] [Full Text] [Related]

  • 2. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
    Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M.
    J Immunother; 2004 Oct; 27(6):432-41. PubMed ID: 15534487
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T, Okamoto M, Ohe G, Furuichi S, Nishikawa H, Uddin Ahmed S, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Anti-cancer effect of an intratumoral injection of dendritic cells expressing TLR4 in combination with an active component of OK-432 in TLR4-deficient mice].
    Oshikawa T, Okamoto M, Ahmed SU, Tano T, Yoshida H, Sato M.
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1770-2. PubMed ID: 15553710
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Akira S, Sato M.
    J Immunother; 2006 Oct; 29(2):143-50. PubMed ID: 16531815
    [Abstract] [Full Text] [Related]

  • 8. [Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
    Tsujimoto H, Tsukioka S, Koizumi K, Nakagawa F, Uchida J, Sugimoto Y, Oka T, Fukushima M, Watanabe T.
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):413-8. PubMed ID: 17353633
    [Abstract] [Full Text] [Related]

  • 9. [Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
    Itoi A, Takashima M, Ishimasa H, Murata H, Tomoda K.
    Gan To Kagaku Ryoho; 2006 May; 33(5):617-20. PubMed ID: 16685159
    [Abstract] [Full Text] [Related]

  • 10. Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice.
    Akutsu Y, Matsubara H, Urashima T, Komatsu A, Sakata H, Nishimori T, Yoneyama Y, Hoshino I, Murakami K, Usui A, Kano M, Ochiai T.
    Int J Oncol; 2007 Sep; 31(3):509-15. PubMed ID: 17671676
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 12. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
    Saji H, Song W, Furumoto K, Kato H, Engleman EG.
    Clin Cancer Res; 2006 Apr 15; 12(8):2568-74. PubMed ID: 16638867
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T, Fukuhara T, Mizuguchi H, Hayakawa T, Saijo Y, Nukiwa T, Kikuchi T.
    Eur J Immunol; 2006 Apr 15; 36(4):1019-27. PubMed ID: 16525992
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
    Yao LC, Yang RJ.
    Zhonghua Yi Xue Za Zhi; 2007 Sep 25; 87(36):2552-6. PubMed ID: 18067832
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H, Oku N, Moriya Y, Kusumoto S, Suda Y.
    Int Immunopharmacol; 2008 Jan 25; 8(1):12-9. PubMed ID: 18068095
    [Abstract] [Full Text] [Related]

  • 17. Angelan isolated from Angelica gigas Nakai induces dendritic cell maturation through toll-like receptor 4.
    Kim JY, Yoon YD, Ahn JM, Kang JS, Park SK, Lee K, Song KB, Kim HM, Han SB.
    Int Immunopharmacol; 2007 Jan 25; 7(1):78-87. PubMed ID: 17161820
    [Abstract] [Full Text] [Related]

  • 18. [Correlation between anti-tumor effect and delayed hypersensitivity induced by topically applied OK-432 with histological findings].
    Kokunai I, Mori T, Yayoi E, Matuura N, Kosaki G.
    Nihon Geka Gakkai Zasshi; 1985 Mar 25; 86(3):258-65. PubMed ID: 3982380
    [Abstract] [Full Text] [Related]

  • 19. [A case of advanced gastric cancer effectively treated by TS-1 for 4 years].
    Ogino H, Misawa T, Nasu T, Ihara Y, Kubo S, Sadamoto Y, Harada N, Nakamura K.
    Gan To Kagaku Ryoho; 2005 Jun 25; 32(6):833-6. PubMed ID: 15984526
    [Abstract] [Full Text] [Related]

  • 20. Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Uddin Ahmed S, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2006 May 25; 6(5):764-73. PubMed ID: 16546707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.